A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors

Published:2022-04 Issue: Volume:166 Page:98-106
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Lin Lin,Pan Hongming,Li Xingya,Zhao Chengling,Sun Jiangtao,Hu Xingsheng,Zhang Yiping,Wang Mengzhao,Ren Xiubao,Luo Xiaoyong,Shan Guoyong,Hui Ai-Min,Wu Zhuli,Liu Huilong,Tian Ling,Shi Yuankai

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference46 articles.

1. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers;Dogan;Clin. Cancer Res.,2012

2. H. Shigematsu, L. Lin, T. Takahashi, M. Nomura, M. Suzuki, Wistuba, II, K.M. Fong, H. Lee, S. Toyooka, N. Shimizu, T. Fujisawa, Z. Feng, J.A. Roth, J. Herz, J.D. Minna, A.F. Gazdar, Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers, J. Natl. Cancer Inst. 97(5) (2005) 339–346. 10.1093/jnci/dji055.

3. Updated frequency of EGFR and KRAS mutations in nonsmall-cell lung cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP);Arrieta;J. Thorac. Oncol.,2015

4. Genomic signature of driver genes identified by target next-generation sequencing in Chinese non-small cell lung cancer;Wen;Oncologist,2019

5. Y.L. Zhang, J.Q. Yuan, K.F. Wang, X.H. Fu, X.R. Han, D. Threapleton, Z.Y. Yang, C. Mao, J.L. Tang, The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis, Oncotarget 7 (48) (2016) 78985-78993. 10.18632/oncotarget.12587.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy;European Journal of Medicinal Chemistry;2024-10

2. Advances in Small-Molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-Cancer Agents;Current Medicinal Chemistry;2024-06-10

3. Rapid Determination of 9 Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma in Human Plasma by QuEChERS-UPLC-MS/MS;Frontiers in Pharmacology;2022-06-21